Abstracts tagged "quality of care"

Abstract Number: 1897 • ACR Convergence 2023
In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care
Aos Aboabat¹, Samar Aboulenain¹, Zareen Ahmad², Medha Soowamber³ and Sindhu Johnson⁴, ¹University of Toronto, Toronto, ON, Canada, ²Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Woodbridge, ON, Canada, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease with significant morbidity and mortality. Quality indicators (QIs) for SSc care, previously published, are essential tools…
Abstract Number: 2094 • ACR Convergence 2023
Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator
Corey Fellon¹, Hannah Bowen² and Lee Shapiro³, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Foundation, Batavia, NY, ³Albany Medical College, Stillwater, NY
Background/Purpose: Scleroderma is a condition that can affect almost every organ system and thus requires an interprofessional team to optimally manage symptoms and improve patient…
Abstract Number: 0433 • ACR Convergence 2023
DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Una Makris², Namrata Singh³, Raymond Yung⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX, ³University of Washington, Bellevue, WA, ⁴Michigan Medicine, Ann Arbor, MI
Background/Purpose: The number of older adults living with rheumatoid arthritis (RA) is growing as the world population is aging. Up to one-third of the older…
Abstract Number: 1088 • ACR Convergence 2023
Improving JIA Outcomes Assessments in a Large Pediatric Rheumatology Practice: A Fellow Quality Improvement Project
Anna Costello¹, Hallie Carol¹, Dori Abel², Sarah Bayefsky³, Sarah Capponi¹, Adam Mayer¹, Julia Rood¹, Kirsten Spichiger¹, Joshua Madas¹, Lynsey Cecere¹, Megan Roman¹, Beth Rutstein⁴ and Jon Burnham², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Rheumatology at Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease that can result in long-term joint damage if inadequately treated. Collecting validated outcomes data at…
Abstract Number: 1898 • ACR Convergence 2023
Patient After Visit Instructions at a University Rheumatology Outpatient Clinic: Do They Make a Difference?
Dijo Joseph, Rong Hu, Robert Min, Meenakshi Jolly and Sobia Hassan, Rush University Medical Center, Chicago, IL
Background/Purpose: As low health literacy (HL) has been linked to poor health outcomes in rheumatic diseases, it is important to optimize organizational HL. One way…
Abstract Number: 2299 • ACR Convergence 2023
Medication-related Hospitalizations in Systemic Lupus Erythematosus
Michele Stanciu¹, Evelyne Vinet², Emily Gibson McDonald³, Gregory Clark³, Christian Pineau², Fares Kalache⁴, Louis-Pierre Grenier⁵, Sasha Bernatsky⁶ and Arielle Mendel³, ¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Carignan, AB, Canada, ⁵Montreal General Hospital, Montréal, QC, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Adverse drug events (ADEs; harm from use of a drug) cause a significant burden to the healthcare system, with an estimated 5% of hospitalizations…
Abstract Number: 0470 • ACR Convergence 2023
Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic
Caroline Siegel¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Erika Abramson², Nancy Pan¹ and Lisa Sammaritano³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Only one-third of reproductive-aged women with rheumatic disease (RD) are prescribed effective contraception, even if prescribed teratogenic medications (Talabi et al. Arthritis Care Res.…
Abstract Number: 1089 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic
Nagendra Pokala¹, Benjamin Gardner², Avni Amratia¹, Daniel Emesiani³, Jiby Mathew⁴, Rashmi Arora⁵, Una Makris⁶ and Swathi Reddy⁷, ¹Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, ³Baylor Scott and White Medical Center McKinney, Dallas, TX, ⁴VA North Texas Healthcare System, Dallas, TX, ⁵Department of Internal Medicine, UT Southwestern Medical Center; VA North Texas Healthcare System, Dallas, TX, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁷UT Southwestern Medical Center / Dallas VA Medical Center, Colleyville, TX
Background/Purpose: Due in part to immunosuppressant medications, patients with rheumatic diseases not only carry a higher risk of herpes zoster reactivation but also worse outcomes.…
Abstract Number: 1899 • ACR Convergence 2023
Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States
Jinoos Yazdany¹, April Jorge², Claire Barber³, April Barnado⁴, Bonnie Bermas⁵, Ali Duarte-Garcia⁶, Amy Bennett⁷, Candace Feldman⁸, Shivani Garg⁹, Leah Haseley¹⁰, Shraddha Jatwani¹¹, Tracy Johansson¹², Alex Limanni¹³, Wambui Machua¹⁴, Wendy Rodgers¹⁵, Brad Rovin¹⁶, Yesenia Santiago-Casas¹⁷, Lisa Suter¹⁸, JoAnn Zell¹⁹, Patti Katz²⁰ and Christie M. Bartels²¹, ¹University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ²Massachusetts General Hospital, Boston, MA, ³University of Calgary, Calgary, AB, Canada, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵UT Southwestern, Dallas, TX, ⁶Mayo Clinic, Rochester, MN, ⁷ACR, Atlanta, GA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹⁰University of Washington, Seattle, WA, ¹¹Dignity Health-MMG Rheumatology, East Norriton, PA, ¹²American College of Rheumatology, Atlanta, GA, ¹³Self, Dallas, TX, ¹⁴Piedmont Healthcare, Atlanta, GA, ¹⁵Lupus Foundation of America, Los Angeles, CA, ¹⁶Ohio State University, Columbus, OH, ¹⁷Guillermo Valenzuela MD PA, Plantation, FL, ¹⁸Yale School of Medicine, New Haven, CT, ¹⁹University of Colorado Anschutz Medical Campus, Denver, CO, ²⁰University of California San Francisco, San Rafael, CA, ²¹University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Collaborating with the Centers for Disease Control and Prevention (CDC), the ACR has developed new quality measures for lupus clinical care, including clinical and…
Abstract Number: 2484 • ACR Convergence 2023
Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management
Ruchi Patel¹, Kristen Salava¹, Eric Newman², Joseph Chronowski¹, Dante Grassi¹, Hillary Harris³, Amanda Young¹, Idorenyin Udoeyo², Lisa Schroeder², David Bulbin⁴, David Pugliese⁵ and Jonida Cote⁶, ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA, ³Geisinger, Wilkes Barre, PA, ⁴Geisinger Health System, Danville, PA, ⁵Geisinger Health System, Wilkes-Barre, PA, ⁶Geisinger Medical Center, Orefield, PA
Background/Purpose: More effective teamwork can improve patient care. We studied the effect of a Rheumatologist-Pharmacist Co-management program on the quality of care of rheumatology patients…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 1091 • ACR Convergence 2023
Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
Raphael Kirou, Cesar Avalos and Ellen Ginzler, SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: Quality of care (QoC) in SLE patients has been studied by Schmajuk et al. (Arthritis Care Res2022), who developed six quality measures assessing blood…
Abstract Number: 1900 • ACR Convergence 2023
Assessment of Hospitalist Confidence Levels in Management of Rheumatic Conditions to Identify Potential Knowledge Gaps
Lily Sung, Amber Young and Jiha Lee, University of Michigan, Ann Arbor, MI
Background/Purpose: Healthcare utilization, including hospitalization, is high among patients with rheumatic musculoskeletal diseases (RMD). As the primary care providers during admission, hospitalists play a key…
Abstract Number: 2556 • ACR Convergence 2023
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
Jiacai Cho¹, Liang Shen², Rangi Kandane-Rathnayake³, Vera Golder³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian J Wu⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹⁴, BMDB Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Shereen Oon²⁰, Sean O’Neill²¹, Fiona Goldblatt²², Kristine Ng²³, Annie Law²⁴, Nicola Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra⁹, Chak Sing Lau²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹, Eric Morand³² and Aisha Lateef³³, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Peking University People’s Hospital, Beijing, China, ¹¹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ¹⁶Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁷Keio University, Keio, Japan, ¹⁸Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²⁰Department of Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²¹Department of Medicine, University of New South Wales, Kensington, Australia, ²²Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²³Waitemata DHB, Auckland, New Zealand, ²⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²⁵Auckland District Health Board, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Manila, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ³²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³³National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore
Background/Purpose: SLE patients suffer high symptom burden at the end-of-life. However, the course of disease and treatment burden in the last year of life have…
Abstract Number: 0752 • ACR Convergence 2023
Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA
Background/Purpose: Screening for latent tuberculosis (TB) is recommended prior to starting biologics or targeted synthetic DMARDs (b/tsDMARDs). With a growing number of these drugs available…

« Previous Page
1
…
5
6
7
8
9
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].